



103RD GENERAL ASSEMBLY

State of Illinois

2023 and 2024

SB0101

Introduced 1/24/2023, by Sen. Laura Fine

SYNOPSIS AS INTRODUCED:

215 ILCS 5/356z.25

Amends the Illinois Insurance Code. Provides that no group or individual policy of accident and health insurance or managed care plan shall deny or delay coverage for medically necessary treatment because the insured, enrollee, or beneficiary previously received any treatment, including the same or similar treatment, for pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections or pediatric acute onset neuropsychiatric syndrome, or because the insured, enrollee, or beneficiary has been diagnosed with or receives treatment for an otherwise diagnosed condition. Provides that coverage of pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections and pediatric acute onset neuropsychiatric syndrome shall adhere to the treatment recommendations developed by a medical professional consortium convened for the purposes of researching, identifying, and publishing best practice standards for diagnosis and treatment of such disorders or syndrome that are accessible for medical professionals and are based on evidence of positive patient outcomes. Provides that coverage for any form of medically necessary treatment shall not be limited over a lifetime of an insured, enrollee, or beneficiary, unless the patient is no longer benefiting from the treatment, or by policy period. Provides that nothing in the provisions prevents insurers from requesting treatment notes and anticipated duration of treatment and outcomes. Effective immediately.

LRB103 25077 BMS 51412 b

1 AN ACT concerning regulation.

2 **Be it enacted by the People of the State of Illinois,**
3 **represented in the General Assembly:**

4 Section 5. The Illinois Insurance Code is amended by
5 changing Section 356z.25 as follows:

6 (215 ILCS 5/356z.25)

7 Sec. 356z.25. Coverage for treatment of pediatric
8 autoimmune neuropsychiatric disorders associated with
9 streptococcal infections and pediatric acute onset
10 neuropsychiatric syndrome. A group or individual policy of
11 accident and health insurance or managed care plan that is
12 amended, delivered, issued, or renewed after July 18, 2017
13 (the effective date of Public Act 100-24) shall provide
14 coverage for treatment of pediatric autoimmune
15 neuropsychiatric disorders associated with streptococcal
16 infections and pediatric acute-onset neuropsychiatric
17 syndrome, including, but not limited to, the use of
18 intravenous immunoglobulin therapy.

19 No group or individual policy of accident and health
20 insurance or managed care plan shall deny or delay coverage
21 for medically necessary treatment under this Section solely
22 because the insured, enrollee, or beneficiary previously
23 received any treatment, including the same or similar

1 treatment, for pediatric autoimmune neuropsychiatric disorders
2 associated with streptococcal infections or pediatric acute
3 onset neuropsychiatric syndrome, or because the insured,
4 enrollee, or beneficiary has been diagnosed with or receives
5 treatment for an otherwise diagnosed condition.

6 For the purposes of this Section, coverage of pediatric
7 autoimmune neuropsychiatric disorders associated with
8 streptococcal infections and pediatric acute onset
9 neuropsychiatric syndrome shall adhere to the treatment
10 recommendations developed by a medical professional consortium
11 convened for the purposes of researching, identifying, and
12 publishing best practice standards for diagnosis and treatment
13 of such disorders or syndrome that are accessible for medical
14 professionals and are based on evidence of positive patient
15 outcomes. Coverage for any form of medically necessary
16 treatment shall not be limited over a lifetime of an insured,
17 enrollee, or beneficiary, unless the patient is no longer
18 benefiting from the treatment, or by policy period. Nothing in
19 this Section prevents insurers from requesting treatment notes
20 and anticipated duration of treatment and outcomes.

21 For billing and diagnosis purposes, pediatric autoimmune
22 neuropsychiatric disorders associated with streptococcal
23 infections and pediatric acute onset neuropsychiatric syndrome
24 shall be coded as autoimmune encephalitis until the American
25 Medical Association and the Centers for Medicare and Medicaid
26 Services create and assign a specific code for pediatric

1 autoimmune neuropsychiatric disorders associated with
2 streptococcal infections and pediatric acute onset
3 neuropsychiatric syndrome. Thereafter, pediatric autoimmune
4 neuropsychiatric disorders associated with streptococcal
5 infections and pediatric acute onset neuropsychiatric syndrome
6 may be coded as autoimmune encephalitis, pediatric autoimmune
7 neuropsychiatric disorders associated with streptococcal
8 infections, or pediatric acute onset neuropsychiatric
9 syndrome.

10 If, at any time, the Secretary of the United States
11 Department of Health and Human Services, or its successor
12 agency, promulgates rules or regulations to be published in
13 the Federal Register or publishes a comment in the Federal
14 Register or issues an opinion, guidance, or other action that
15 would require the State, pursuant to any provision of the
16 Patient Protection and Affordable Care Act (Public Law
17 111-148), including, but not limited to, 42 U.S.C.
18 18031(d)(3)(B) or any successor provision, to defray the cost
19 of any coverage for pediatric autoimmune neuropsychiatric
20 disorders associated with streptococcal infections and
21 pediatric acute onset neuropsychiatric syndrome outlined in
22 this Section, then the requirement that an insurer cover
23 pediatric autoimmune neuropsychiatric disorders associated
24 with streptococcal infections and pediatric acute onset
25 neuropsychiatric syndrome is inoperative other than any such
26 coverage authorized under Section 1902 of the Social Security

1 Act, 42 U.S.C. 1396a, and the State shall not assume any
2 obligation for the cost of coverage for pediatric autoimmune
3 neuropsychiatric disorders associated with streptococcal
4 infections and pediatric acute onset neuropsychiatric
5 syndrome.

6 (Source: P.A. 100-24, eff. 7-18-17; 100-863, eff. 8-14-18;
7 101-488, eff. 8-23-19.)

8 Section 99. Effective date. This Act takes effect upon
9 becoming law.